RetinalGenix Technologies Inc. (RTGN)
| Market Cap | 67.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.76M |
| Shares Out | 18.52M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 246 |
| Open | 3.650 |
| Previous Close | 5.020 |
| Day's Range | 3.650 - 3.650 |
| 52-Week Range | 0.250 - 6.360 |
| Beta | -3.87 |
| RSI | 49.18 |
| Earnings Date | Aug 14, 2025 |
About RetinalGenix Technologies
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-20... [Read more]
Financial Performance
Financial StatementsNews
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
Appointment Underscores RetinalGenix's Commitment to Integrating the Latest Advances in Genomics and Personalized Medicine into its Product Pipeline Appointment Underscores RetinalGenix's Commitment t...
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
Company to use facility to further development of RetinalGenix's therapies for neurodegenerative and retinal diseases Company to use facility to further development of RetinalGenix's therapies for neu...
RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
RetinalGenix Technologies to Participate at 2025 Roth Conference and will discuss patented remote monitoring high-resolution retinal imaging and biomarkers
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring
RETINALGENIX TECHNOLOGIES BREAKTHROUGH IN REAL-TIME 24/7 REMOTE OCULAR MONITORING High-Resolution Retinal Imaging Using Both Near Infrared And Green Modes
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United State...
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company's Medical Advisory Board
PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
RETINALGENIX TECHNOLOGIES INC. APPOINTS DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
PETALUMA, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”) today announced that it has hired Virender Ahluwalia as Interim Chief...
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business A...
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applica...
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide gu...
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
Video Presentation Highlights Combining Genetic Markers with High-Resolution Retinal Imaging to Aid in Detection and Treatment of Blindness and Multiple Systemic Diseases Video Presentation Highlights...
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical...
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
Technology Enables Physicians to Remotely Make Pre-Diagnostic Assessment Regarding Whether an In-Person Diagnostic Examination of Ocular Anatomy is Warranted Technology Enables Physicians to Remotely ...
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
Study Intends To Identify Hematology Biomarkers That May Help Personalize Medical Evaluations For Patients Undergoing Treatments For Macular Degeneration Study Intends To Identify Hematology Biomarker...
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
Watson Hired to Accelerate DNA-Based "GPS" Genetic Testing App Which Combines with RTGN's High-Resolution Retinal Imaging Technologies Seeking to Revolutionize Diagnosis of Systemic Diseases Watson Hi...
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
RetinalGeniX Technologies Invites Individual and Institutional Investors, Advisors, and Analysts, to Attend its Real-Time, Interactive Presentation at The Emerging Growth Conference RetinalGeniX Techn...
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
Appointment Expected to Support Initiatives to Improve Population Health Management and the Company's Planned Listing Upgrade from OTCBQB to NASDAQ Appointment Expected to Support Initiatives to Impro...
RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.
Acquisition of DNA-Based "GPS" Genetic Testing Combines with RTGN's High Resolution Retinal Imaging Technologies Seeks to Revolutionize Diagnosis of Systemic Diseases Acquisition of DNA-Based "GPS" Ge...
RetinalGeniX™Technologies, Inc. Announces Listing to OTCQB Venture Market
PETALUMA, Calif., March 8, 2022 /PRNewswire/ -- RetinalGeniX™Technologies, Inc. (OTCQB: RTGN), www.retinalgenix.com announced today it commenced trading on the OTCQB® Venture Market, under the symbol ...